drug resistance caused by epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer, we used the principle of collocation to design and synthesize a series of aminopyrimidine derivatives with 4,5,6,7-tetrahydrothieno [3,2-c]pyridine side chains (according to the binding mode of AZD9291 to EGFRT790M) for use as EGFRL858R/T790M kinase inhibitors. The most promising compound A12,
为解决非小细胞肺癌
表皮生长因子受体(
EGFR)突变引起的耐药问题,我们利用搭配原理,设计合成了一系列含4,5,6,7-
四氢噻吩的
氨基嘧啶衍
生物。 [3,2-c]
吡啶侧链(根据
AZD9291 与
EGFR T790M的结合模式)用作
EGFR L858R/T790M激酶
抑制剂。最有前途的化合物
A12是一种非共价结合的可逆
抑制剂,对
EGFR L858R/T790M表现出优异的激酶抑制活性,IC 50值为 4.0 nM,对
EGFR WT的选择性超过 42 倍(IC 50 = 170.0 nM) . 此外,复合
A12对H1975细胞具有很强的抗增殖活性,IC 50值为0.086 μM。此外,
A12对细胞迁移的有效抑制和对细胞凋亡的促进验证了其作用机制,作为
EGFR L858R/T790M的选择性
抑制剂。